BRPI0910979A2 - compostos e composições como inibidores de quinase - Google Patents

compostos e composições como inibidores de quinase

Info

Publication number
BRPI0910979A2
BRPI0910979A2 BRPI0910979A BRPI0910979A BRPI0910979A2 BR PI0910979 A2 BRPI0910979 A2 BR PI0910979A2 BR PI0910979 A BRPI0910979 A BR PI0910979A BR PI0910979 A BRPI0910979 A BR PI0910979A BR PI0910979 A2 BRPI0910979 A2 BR PI0910979A2
Authority
BR
Brazil
Prior art keywords
compositions
compounds
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
BRPI0910979A
Other languages
English (en)
Inventor
Baogen Wu
Pierre-Yves Michellys
Tao Jiang
Truc Ngoc Nguyen
Wei Pei
Xuefeng Zhu
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0910979A2 publication Critical patent/BRPI0910979A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0910979A 2008-04-07 2009-04-03 compostos e composições como inibidores de quinase BRPI0910979A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US9588308P 2008-09-10 2008-09-10
PCT/US2009/039380 WO2009126514A1 (en) 2008-04-07 2009-04-03 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0910979A2 true BRPI0910979A2 (pt) 2016-01-05

Family

ID=40786670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910979A BRPI0910979A2 (pt) 2008-04-07 2009-04-03 compostos e composições como inibidores de quinase

Country Status (13)

Country Link
US (1) US8518931B2 (pt)
EP (1) EP2271645A1 (pt)
JP (1) JP5214799B2 (pt)
KR (1) KR20110002080A (pt)
CN (1) CN102056925A (pt)
AR (1) AR071300A1 (pt)
AU (1) AU2009233963B2 (pt)
BR (1) BRPI0910979A2 (pt)
CA (1) CA2720944C (pt)
EA (1) EA018484B1 (pt)
MX (1) MX2010011069A (pt)
UY (1) UY31750A (pt)
WO (1) WO2009126514A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2300013B2 (en) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
JP5364159B2 (ja) 2009-05-08 2013-12-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2867233A1 (en) 2012-07-03 2015-05-06 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
CA2890006C (en) 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
BR112016022105B1 (pt) * 2014-03-27 2023-01-31 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5- a]pirazina substituídos e derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inibidores do ros1 e composição farmacêutica que os compreende
EP3778605A3 (en) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (pt) 1973-05-22 1974-11-26
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CA2497544C (en) * 2002-09-04 2010-11-02 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
KR20050115252A (ko) * 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
EP1671962A1 (en) * 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
JP2006160628A (ja) * 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
EP1836205B1 (en) * 2004-12-21 2009-06-10 Schering Corporation PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
WO2009126514A8 (en) 2010-10-21
US8518931B2 (en) 2013-08-27
AU2009233963B2 (en) 2011-10-06
CA2720944C (en) 2012-12-18
CN102056925A (zh) 2011-05-11
JP2011516554A (ja) 2011-05-26
AR071300A1 (es) 2010-06-09
KR20110002080A (ko) 2011-01-06
EP2271645A1 (en) 2011-01-12
WO2009126514A1 (en) 2009-10-15
EA018484B1 (ru) 2013-08-30
US20110190264A1 (en) 2011-08-04
CA2720944A1 (en) 2009-10-15
JP5214799B2 (ja) 2013-06-19
MX2010011069A (es) 2010-11-12
UY31750A (es) 2009-12-14
AU2009233963A1 (en) 2009-10-15
EA201001596A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
CY2019027I1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
LTPA2019006I1 (lt) Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0914545A2 (pt) compostos e composições como inibidores de quinase
BRPI0908849A2 (pt) Composto e composições como c-kit e inibidores de pdgfr quinase
BRPI0811516A2 (pt) Compostos e composições como inibidores de c-kit e pdgfr cinase
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
DK2634231T3 (da) Sammensætninger
BRPI0908494A2 (pt) Inibidores de pirrolopirazina quinase
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
EP2381760A4 (en) CORN PROTEIN COMPOSITION
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.